Kidney drug finerenone shows promise for millions beyond diabetes patients

Chronic kidney disease affects approximately 850 million people worldwide and is a major cause of illness and death, with risks of hospitalization and cardiovascular complications increasing as disease advances.

For the roughly 850 million people living with chronic kidney disease — most of them without diabetes and most of them without meaningful treatment options — a convergence of clinical evidence offers something rare: a reason for cautious hope. Three simultaneous trials, published across medicine's most prestigious journals in June 2026, found that finerenone meaningfully slows kidney decline and reduces cardiovascular death across a far broader population than the drug was originally designed to serve. The findings arrive against a backdrop of projected crisis, with kidney disease on course to

Kidney drug finerenone shows promise for millions beyond diabetes patients

Cobertura Relacionada

Receba o Register no seu e-mail